根治的前立腺全摘278症例の臨床的検討

元データ 泌尿器科紀要刊行会

概要

A retrospective analysis was done on the outcomes of 278 patients who underwent radical prostatectomies at our institutions from November, 1994 to April, 2006. The treatment outcomes measured were disease-specific survival and prostate specific antigen (PSA) biochemical failure-free survival rates. Univariate and multivariate analyses were performed on patient age, clinical T-stage, Gleason sum at the time of prostate biopsy, PSA value before treatment, and any patient history of neoadjuvant hormone therapy. For all patients, the overall survival and the disease-specific survival rates at 10 years were 96.3 and 99.3%, respectively, with PSA biochemical failure-free survival rates at 5 and 10 years of 67.9 and 55.1%, respectively. On multivariate analysis, both the PSA values (> 20 ng/ml) and Gleason sums (> or = 7) were statistically significant independent risk factors for PSA biochemical failure after radical prostatectomy. Neoadjuvant hormone therapy was found to have no effect on PSA biochemical failure.

著者

長谷川 嘉弘 三重大学大学院医学系研究科腎泌尿器外科学
西川 晃平 三重大学大学院医学系研究科腎泌尿器外科学
曽我 倫久人 三重大学医学部腎泌尿器外科学
長谷川 嘉弘 三重大学医学部附属病院腎泌尿器外科

関連論文

▼もっと見る